Krystal Biotech receives approval in Europe for gene therapy treatment
April 19, 2018 at 12:31 PM EDT
The designation by the European Medicines Agency is for KB103, a gene therapy treatment for an incurable skin-blistering condition.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.